Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Moritz

Showing results (161-170 of 190) with videos related to

Pageof 19
Sort By:
Journal of Applied Physiology (Bethesda, Md. : 1985)|July 11, 2009
Robust passive dynamics of the musculoskeletal system compensate for unexpected surface changes during human hoppingMarjolein M van der Krogt, Wendy W de Graaf, Claire T Farley, et al.
Circulation|August 1, 1991
Starting aspirin therapy after operation. Effects on early graft patency. Department of Veterans Affairs Cooperative Study GroupS Goldman, J Copeland, T Moritz, et al.
Circulation|March 1, 1994
Long-term graft patency (3 years) after coronary artery surgery. Effects of aspirin: results of a VA Cooperative studyS Goldman, J Copeland, T Moritz, et al.
Gene Therapy|July 1, 2015
Tightly regulated 'all-in-one' lentiviral vectors for protection of human hematopoietic cells from anticancer chemotherapyN Lachmann, S Brennig, R Hillje, et al.
Circulation|November 1, 1990
Internal mammary artery and saphenous vein graft patency. Effects of aspirinS Goldman, J Copeland, T Moritz, et al.
Gene Therapy|May 18, 2012
Efficient in vivo regulation of cytidine deaminase expression in the haematopoietic system using a doxycycline-inducible lentiviral vector systemN Lachmann, S Brennig, N Pfaff, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1992
Tumor necrosis factor alpha modifies resistance to interferon alpha in vivo: first clinical dataT Moritz, O Kloke, M Nagel-Hiemke, et al.
British Journal of Haematology|August 1, 1992
Combination therapy with interferon alpha-2b plus low-dose interferon gamma in pretreated patients with Ph-positive chronic myelogenous leukaemiaU B Wandl, O Kloke, M Nagel-Hiemke, et al.
Gene Therapy|October 7, 2011
MicroRNA-150-regulated vectors allow lymphocyte-sparing transgene expression in hematopoietic gene therapyN Lachmann, J Jagielska, D Heckl, et al.
Diabetes, Obesity & Metabolism|May 13, 2015
Rosiglitazone treatment and cardiovascular disease in the Veterans Affairs Diabetes TrialH Florez, P D Reaven, G Bahn, et al.
Pageof 19

Showing results (161-170 of 190) with videos related to

Sort By:
Pageof 19
Journal of Applied Physiology (Bethesda, Md. : 1985)|July 11, 2009
Robust passive dynamics of the musculoskeletal system compensate for unexpected surface changes during human hoppingMarjolein M van der Krogt, Wendy W de Graaf, Claire T Farley, et al.
Circulation|August 1, 1991
Starting aspirin therapy after operation. Effects on early graft patency. Department of Veterans Affairs Cooperative Study GroupS Goldman, J Copeland, T Moritz, et al.
Circulation|March 1, 1994
Long-term graft patency (3 years) after coronary artery surgery. Effects of aspirin: results of a VA Cooperative studyS Goldman, J Copeland, T Moritz, et al.
Gene Therapy|July 1, 2015
Tightly regulated 'all-in-one' lentiviral vectors for protection of human hematopoietic cells from anticancer chemotherapyN Lachmann, S Brennig, R Hillje, et al.
Circulation|November 1, 1990
Internal mammary artery and saphenous vein graft patency. Effects of aspirinS Goldman, J Copeland, T Moritz, et al.
Gene Therapy|May 18, 2012
Efficient in vivo regulation of cytidine deaminase expression in the haematopoietic system using a doxycycline-inducible lentiviral vector systemN Lachmann, S Brennig, N Pfaff, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1992
Tumor necrosis factor alpha modifies resistance to interferon alpha in vivo: first clinical dataT Moritz, O Kloke, M Nagel-Hiemke, et al.
British Journal of Haematology|August 1, 1992
Combination therapy with interferon alpha-2b plus low-dose interferon gamma in pretreated patients with Ph-positive chronic myelogenous leukaemiaU B Wandl, O Kloke, M Nagel-Hiemke, et al.
Gene Therapy|October 7, 2011
MicroRNA-150-regulated vectors allow lymphocyte-sparing transgene expression in hematopoietic gene therapyN Lachmann, J Jagielska, D Heckl, et al.
Diabetes, Obesity & Metabolism|May 13, 2015
Rosiglitazone treatment and cardiovascular disease in the Veterans Affairs Diabetes TrialH Florez, P D Reaven, G Bahn, et al.
Pageof 19